Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 14/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PELI1 | Q96FA3 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4384367 | 0.82 | GPR183 (0.48) | GPR183SMN1; SMN2 | |
| SCHEMBL14190947 | 0.82 | GPR183 (0.48) | GPR183SMN1; SMN2 | |
| SCHEMBL13636495 | 0.75 | ACHE (0.45) | GPR183SMN1; SMN2PELI1MAPT | |
| SCHEMBL13090259 | 0.73 | PELI1 (0.52) | GPR183SMN1; SMN2PELI1MAPT | |
| SCHEMBL31238165 | 0.73 | ERN1 (0.60) | HSP90AA1MAPTMAPK1NPSR1 | |
| SCHEMBL4378517 | 0.72 | NPC1 (0.64) | GPR183SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL13636477 | 0.72 | NPC1 (0.64) | GPR183SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL13636009 | 0.71 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL4380888 | 0.71 | JUN (0.57) | SMN1; SMN2MAPT | |
| SCHEMBL4377280 | 0.71 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | disclosed |